I Think IBM Stock Will Be Higher in 5 Years. I Still Wouldn't Buy It Today.

IBM's Q2 revenue rose only 1% year over year to $17.2 billion, prompting management to cut its 2026 constant-currency revenue-growth outlook to 4%-5%; shares are down about 22% year to date after a roughly 25% July 14 sell-off. Software growth slowed to 5% from 11% in Q1, consulting was flat, and infrastructure revenue fell 7%, highlighting execution and demand risks in the core growth business. IBM still forecasts roughly $15.7 billion of 2026 free cash flow, up about $1 billion, supporting its $1.69 quarterly dividend and nearly 3% yield, while its 2029 fault-tolerant quantum roadmap remains a longer-term upside catalyst.

Analysis

IBM’s drawdown has shifted the debate from AI optionality to whether its recurring-software base can sustain even mid-single-digit growth. The key issue is operating leverage: a modest software reacceleration can restore mix and earnings confidence, but another quarter of low-single-digit growth would make the current forward multiple vulnerable despite healthy cash conversion. Infrastructure weakness should ease as the mainframe cycle laps, but that is not a growth catalyst; it merely removes a drag.

The more important second-order signal is customer IT-budget allocation. If enterprises are pre-buying hardware because of component inflation, that implies near-term wallet share is moving away from software, consulting, and potentially cloud consumption. This is unfavorable for IBM and also warrants monitoring for IT-services peers ACN and DXC; conversely, it supports hardware and memory-exposed beneficiaries such as DELL, HPE, MU, and WDC if the spend shift persists through the next two quarters.

The market is likely correct not to capitalize quantum value today. The relevant 6-18 month catalyst is instead software bookings, renewal rates, and large-deal conversion—not a 2029 technical milestone or non-dilutive research funding. A durable recovery requires evidence that delayed deals closed without incremental pricing concessions and that software growth returns to at least high-single digits; absent that, IBM becomes a low-growth yield vehicle whose valuation floor is lower than investors assume.

Contrarianly, the post-earnings move may be overdone if the slowdown is principally procurement timing plus a temporary hardware-led budget distortion. But that view needs confirmation in the next reported quarter: backlog conversion and software growth matter more than free-cash-flow guidance, which can be protected temporarily by working capital, capex timing, or expense controls.

Key Decisions for Investors

• Remain neutral/underweight IBM over the next 1-3 months; do not treat the dividend as downside protection. Reassess only if software revenue growth reaccelerates to at least 8% and management confirms delayed large-deal closures without further full-year guidance cuts.
• Use a tactical relative-value trade: long DELL or HPE versus short IBM through the next earnings cycle, sized modestly. The thesis is continued enterprise budget rotation toward servers/storage; exit if IBM software growth exceeds 8% or hardware order commentary weakens materially. Target 10-15% relative return with roughly 7% stop-loss on the spread.
• For long-only exposure, set a staged-entry alert rather than buy immediately: initiate IBM only after evidence of bookings conversion, or on a valuation reset below approximately 15x forward earnings with free-cash-flow guidance intact. The upside case is multiple normalization; the risk is another guidance reset and a de-rating toward mature IT-services peers.
• Monitor ACN and DXC for consulting-spend read-through, and MU/WDC for confirmation that component-price expectations are extending hardware purchases. A broadening hardware-led capex cycle would validate the near-term substitution thesis; a rapid reversal would remove a key explanation for IBM’s weak software and consulting trajectory.